ImmunoNova represents the evolution of the Controfasico protocol, the result of more than twenty years of clinical experience and scientific research in the treatment of vitiligo.

ImmunoNova was created as the natural evolution of the Controfasico protocol, with the goal of offering patients not only a more comprehensive therapy, but also one more aligned with the latest scientific knowledge.

The clinical experience gained over years of work has shown that combating vitiligo requires more than acting locally on the skin: it requires a systemic vision, capable of considering the disease for what it truly is — a complex autoimmune condition.

The right therapy at the right time

Vitiligo does not follow a uniform course. There are phases in which the disease is active and others in which it tends to stabilize. ImmunoNova responds to this variability by adapting therapy to the patient’s clinical condition. Periodic monitoring with the VAI and Wood’s lamp makes it possible to determine whether the disease is progressing or stable, guiding therapeutic decisions:
Periodic monitoring with the Vitiligo Activity Index (VAI) and Wood’s lamp allows physicians to establish precisely whether the disease is progressing or stable. In this way, the doctor can choose the most appropriate intervention each time:

• during active phases, treatments aimed at rebalancing the immune system,
• during stable phases, strategies that stimulate repigmentation and consolidate results.

This adaptive approach makes it possible to provide each patient with the most effective therapy at the right time, promoting long-lasting clinical results.

ImmunoNova is an integrated therapeutic protocol developed as the evolution of the Controfasico approach, combining accurate diagnosis, systemic strategies, and targeted local therapies. Its goal is to treat vitiligo comprehensively, acting not only on the skin but also on the immune mechanisms underlying the disease.
The treatment pathway is structured around five fundamental pillars:

1. Clinical evaluation with the VAI (Vitiligo Activity Index, an index that measures disease activity) and Wood’s lamp. Every patient is evaluated through objective tools that make it possible to determine whether vitiligo is in an active or stable phase.
2. Correction of gastrointestinal dysfunctions: Intestinal well-being is an integral part of vitiligo management. Through a targeted dietary approach, efforts are made to restore the intestinal barrier and reduce systemic inflammation.
3. Microbiota and Vitamin D3: Repopulation of the microbiota with specific strains and monitoring of vitamin D3 contribute to rebalancing the immune response and strengthening immune tolerance.
4. Home-based narrowband UVB phototherapy: A daily, safe, and personalized therapy that uses narrowband phototherapy to stimulate repigmentation in a constant and controlled way.
5. Targeted topical therapies: Application of immunomodulating molecules or melanocyte-stimulating agents which, in synergy with the other pillars, promote the return of skin pigmentation.

The integration of these elements allows ImmunoNova to adapt to the course of the disease and to offer a personalized therapeutic pathway, with results that are documentable and sustainable over time.

The ImmunoNova Protocol can only be prescribed by a physician with specific experience in the management of vitiligo.

At Dermacademy, the evaluation is carried out by the clinical team led by Dr. Giovanni Menchini, who is recognized as a European reference in the study and treatment of vitiligo.

The physician is responsible for:

• determining the activity status of the disease through the VAI (Vitiligo Activity Index) and Wood’s lamp,
• defining the most appropriate therapeutic pathway, choosing among the different components of the protocol,
• monitoring results through periodic reassessments and adapting therapies according to clinical evolution,
• ensuring that every phase of treatment is safe, personalized, and scientifically validated.

ImmunoNova is therefore not a set of treatments that can be independently replicated, but a structured medical protocol that requires specialist expertise and constant follow-up to ensure consistency, effectiveness, and long-term sustainability.